Development of o/w emulsion formulation for carbamazepine by using modified cyclodextrins

Acta Pharmaceutica

Volumn 52, Issue 3, 2002, Pages 149-159

  Bećirević Laćan, Mira ^a   Jug, Mario ^a   Bačić Vrca, Vesna ^a   Cetina Čižmek, Biserka ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Carbamazepine inclusion complexes; Dimethyl cyclodextrin; Hydroxypropyl ; o w emulsion; Stability constant; Transfer rate constant

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CARBAMAZEPINE; HEPTAKIS(2,6 O DIMETHYL) BETA CYCLODEXTRIN; WATER OIL CREAM;

ARTICLE; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; FREEZE DRYING; MICROEMULSION; MOLECULAR STABILITY; SPRAY DRYING;

EID: 0036753845     PISSN: 13300075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. C. J. Betlach, M. A. Gonzales, B. C. McKiernan, C. Neff-Davis and N. Bodor, Oral pharmacokinetics of carbamazepine in dogs from commercial tablets and a cyclodextrin complex, J. Pharm. Sci. 82 (1993) 1058-1060.
2. H. El-Zein, L. Riad and A. A. El-Bary, Enhancement of carbamazepine dissolution: In vitro and in vivo evaluation, Int. J. Pharm. 168 (1998) 209-220.
3. O. A. Lake, M. Olling and D. M. Barends, In vitro/in vivo correlation of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers, Eur. J. Pharmaceut. Biopharm. 48 (1999) 13-19.
4. Y. Kobayashi, S. Ito, S. Itai and K. Yamamoto, Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate, Int. J. Pharm. 193 (2000) 137-146.
5. M. E. Brewster, W. R. Anderson, K. S. Estes and N. Bodor, Development of aqueous perenteral formulation for carbamazepine through the use of modified cyclodextrins, J. Pharm. Sci. 80 (1991) 380-383.
6. M. E. Brewster, W. R. Anderson, D. Meinsma, D. Moreno, A. I. Webb, L. Pablo, K. S. Estes, H. Derendorf, N. Bodor, R. Sawchuk, B. Cheung and E. Pop, Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-β-cyclodextrin-based formulation of carbamazepine in the dog: Comparision with commercially available tablets and suspensions, J. Pharm. Sci. 86 (1997) 335-339.
7. T. Higuchi and K. A. Connors, Phase-solubility techniques, Adv. Anal. Chem. Instr. 4 (1965) 117-212.
8. G. Dollo, P. LeCorre, F. Chevanne, R. LeVerge, Inclusion complexation af amide-type local anaestetics with β-cyclodextrin and its derivates. II. Evaluation of affinity constants and in vitro transfer rate constants, Int. J. Pharm. 136 (1996) 165-174.
9. T. Irie, K. Uekama, Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation, J. Pharm. Sci. 86 (1997) 147-162.
10. F. Giordano, C. Novak, J. R. Moyano, Thermal analysis of cyclodextrins and their inclusion compounds, Thermochim. Acta 380 (2001) 123-151.
11. H. W. Frijlink, A. J. M. Schoonen and C. F. Lerk, The effects of cyclodextrins on drug absorption. I. In vitro observations, Int. J. Pharm. 49 (1989) 91-102.
12. H. Arima, T. Irie and K. Uekama, Differences in the enhancing effects of water soluble β-cyclodextrins on the release of ethyl 4-biphenyl acetate, an anti-inflammatory agent from an oleaginous suppository base, Int. J. Pharm. 57 (1989) 107-115.